Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

OBJECTIVES: This integrated analysis presents the safety profile of upadacitinib, a Janus kinase inhibitor, at 15 mg and 30 mg once daily in patients with moderately to severely active rheumatoid arthritis (RA). METHODS: Treatment-emergent adverse events (TEAEs) and laboratory data from five randomi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Ann Rheum Dis
Главные авторы: Cohen, Stanley B, van Vollenhoven, Ronald F, Winthrop, Kevin L, Zerbini, Cristiano A F, Tanaka, Yoshiya, Bessette, Louis, Zhang, Ying, Khan, Nasser, Hendrickson, Barbara, Enejosa, Jeffrey V, Burmester, Gerd R
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Publishing Group 2021
Предметы:
Rheumatoid Arthritis
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7892382/
https://ncbi.nlm.nih.gov/pubmed/33115760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2020-218510
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы